Losartan Potassium Tablet, Film Coated
Product Images NDC 71610-207

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71610-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 50 mg (71610 0207 30)

Label for Losartan Potassium 50 mg film-coated tablets, containing 30 tablets per package. The label includes storage instructions to keep between 20-25 degrees Celsius and to dispense in a tight light-resistant container. Manufactured by Zhejiang Huahai Pharmaceuticals Co., Ltd. and labeled by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN 38506. The product is for prescription use only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of losartan potassium, the active ingredient in Losartan Potassium 50 mg film-coated tablets by Aphena Pharma Solutions - Tennessee, LLC.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with a primary endpoint over study months (0 to 66) for Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows adjusted risk reduction of 13% with a p-value of 0.021, indicating statistical significance.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over months of a study, showing two treatment groups: Atenolol (dotted line) and Losartan Potassium (solid line). The graph illustrates that Losartan Potassium is associated with a lower percentage of such events over 66 study months, with an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot chart titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol in two categories: Primary Composite and Stroke (Fatal/Non-fatal). The chart shows event rates (%) for different subgroups by age, gender, race, ISH, diabetes, and history of cardiovascular disease with hazard ratios and 95% confidence intervals. Symbols' sizes correspond to sample sizes for each subgroup, indicating treatment effects favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A Kaplan-Meier curve comparing percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The graph indicates a 16.1% risk reduction with Losartan Potassium compared to placebo, with a p-value of 0.022, showing divergence between the treatment and placebo event rates over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.